ArticleCells2019
Mechanism-Specific Pharmacodynamics of a Novel Complex-I Inhibitor Quantified by Imaging Reversal of Consumptive Hypoxia with [
Open access · goldAbstract read
In one paragraph
Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia.RSC medicinal chemistry · 2026Article
- Measuring hypoxia in chronic limb-threatening ischemia usingEJNMMI research · 2025Article
- Targeting Mitochondria in Glioma: New Hopes for a Cure.Biomedicines · 2024Review
- Inhibition of OXPHOS induces metabolic rewiring and reduces hypoxia in murine tumor models.Clinical and translational radiation oncology · 2024Article
- The regulation of hypoxia-related lncRNAs in hepatocellular carcinoma.Discover oncology · 2024Review
- Characterizing OXPHOS inhibitor-mediated alleviation of hypoxia using high-throughput live cell-imaging.Cancer & metabolism · 2024Article
- Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration.JCI insight · 2024Article
- Complex II ambiguities-FADHThe Journal of biological chemistry · 2024Review
- Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism.bioRxiv : the preprint server for biology · 2023Article
- Positron emission tomography imaging of the sodium iodide symporter senses real-time energy stress in vivo.Cancer & metabolism · 2023Article
- Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis.Nature communications · 2023Article
- Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment ofJournal of medicinal chemistry · 2022Article
- Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Review
- Review
- Targeting cancer metabolism in the era of precision oncology.Nature reviews. Drug discovery · 2022Review
- The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.Frontiers in pharmacology · 2022Review
- Excess exogenous pyruvate inhibits lactate dehydrogenase activity in live cells in an MCT1-dependent manner.The Journal of biological chemistry · 2021Article
- Letter to the editor: Hypoxia kinetics and histology in combined radiotherapy and oxidative phosphorylation inhibition effects on antitumor immunity.Journal for immunotherapy of cancer · 2021Article
- Why Great Mitotic Inhibitors Make Poor Cancer Drugs.Trends in cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Seth T GammonDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Federica PisaneschiDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Madhavi L BandiTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Melinda G SmithTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yuting SunTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Yi RaoDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Florian MullerDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Franklin WongDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
John De GrootDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,77030, USA.
Jeffrey AckroydDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Osama MawlawiDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael A DaviesDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Y N Vashisht GopalDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
M Emilia Di FrancescoInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph R MarszalekTranslational Research to Advance Therapeutics and Innovation in Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Mark DewhirstDepartment of Radiation Oncology, Duke University School of Medicine, Durham, NC 27710, USA.
David Piwnica-WormsDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USDuke University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M[18F]FAZA PET/CT for Monitoring Target Engagement of a Novel Complex I InhibitorR01CA231506 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI PIWNICA-WORMS, DAVID · 2019 to 2020
$610kNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001NCI NIH HHS R01 CA231506
Abstract
Tumors lack a well-regulated vascular supply of O
Indexed as
AnimalsBiomarkers, TumorBrain NeoplasmsCell Line, TumorElectron Transport Complex IFemaleGlioblastomaHumansInhibitory Concentration 50MiceMice, NudeNitroimidazolesOxadiazolesOxidative PhosphorylationOxygenPiperidinesBiomarkers, TumorElectron Transport Complex Ifluoroazomycin arabinosideNitroimidazolesOxadiazolesOxygenPiperidinesRadiopharmaceuticals[18F]FAZAcollateral lethalityhypoxiaIACS-010759metabolismmitochondrial complex Ioxidative phosphorylationPETpharmacodynamics
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.